Plain-English translation of NCT07323914 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This research study is testing whether oxycodone/acetaminophen—a combination pain reliever—can help people with Alzheimer's disease who have moderate to severe chronic pain. Researchers will give this medication to 10 participants for 12 weeks and carefully measure how well it works and whether it causes any side effects. The goal is to find better ways to manage pain in people with dementia, who often cannot easily tell doctors how much pain they're in.
People with Alzheimer's disease frequently experience chronic pain but have difficulty communicating their discomfort to caregivers and doctors. This study exists to determine whether the medication can safely relieve pain in this vulnerable population and to establish best practices for pain management in dementia care.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would take a daily dose of the pain medication for 12 weeks. You'll visit the hospital for check-ins at the start, at 6 weeks, and at 12 weeks, where doctors will measure your pain levels and ask about any side effects. After the 12 weeks of treatment end, you'll have one more follow-up visit. Your caregiver will be asked to help track how you're doing and support you throughout the study.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China